Skip to main content
. 2019 Apr 24;11(4):577. doi: 10.3390/cancers11040577

Figure 1.

Figure 1

Group mean TVs from treatment initiation to study end. Data plotted through point when ≥50% of animals in group survived. Error bars = ±1 Std. dev. (A) 786-O xenografts; n = 3/group; treatment was initiated 7 days after tumor implant when group mean TVs ranged from 336–427 mm3. (B) UM-UC-3 xenografts; n = 9 or 10/group; treatment was initiated 18 days after tumor implant when group mean TVs ranged from 161–164 mm3. * p < 0.0001 vs. 3× IT Vehicle; # p < 0.01 for 3× IV Docetaxel 30 mg/kg vs. 2× and 3× NanoDoce® 100 mg/kg groups. (C) PC-3 xenografts; n = 10/group; treatment was initiated 26 days after tumor implant when group mean TVs ranged from 136–141 mm3. * p < 0.0001 vs. 3× IT Vehicle. Statistical significance was determined using one-way ANOVA with Dunnett’s post-test analysis. In all studies, red triangles designate days of treatment.